Of note, CD47 blockade alone is sufficient to prolong survival of random de novo T-ALL PDX models, since all mice treated with anti-CD47 antibodies showed long-term survival with none of the mice developing leukemia, whereas monotherapy with daratumumab only displayed prolonged survival in 67% of the cases and the combined treatment had no further survival benefit. The gene discussed is CD47; the disease is leukemia.